Homo sapiens
Ontology highlight
ABSTRACT:
OTHER RELATED OMICS DATASETS IN: E-GEOD-46590
PROVIDER: PRJNA201057 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:PAD4 is overexpressed in many cancer cells. We developed PAD inhibitors that efficiently inhibit the cancer cell growth. One inhibitor YW3-56 could efficiently induce cell death of triple negative breast cancer MDA-MB-231 cells. We used microarray to detail the global gene expression of MDA-MB-231 before and after YW3-56 treatment and identify significant up-regulated or down-regulated genes by YW3-56 MDA-MB-231 cells were cultured and treated with vehicle (DMSO) or YW3-56. Cells were washed with PBS and harvested for RNA extraction and hybridization on Affymetrix microarray.
2015-05-21 | E-GEOD-46590 | biostudies-arrayexpress
Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h.Sample IDs:#1-5 Control 30 min DLD-1#6-10 FT671 30 min DLD-1#11-15 WEHI-092 30 min DLD-1#16-20 Control 360 min DLD-1#21-25 FT671 360 min DLD-1#26-30 WEHI-092 360min DLD-1#31-35 Control 30 min MDA-MB-231#36-40 WEHI-092 30 min MDA-MB-231#41-45 Control 360 min MDA-MB-231#46-50 WEHI-092 360 min MDA-MB-231#51-55 Control 24 h MDA-MB-231#56-60 WEHI-092 24 h MDA-MB-231
2026-04-09 | PXD073869 | Pride
Project description:K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231
2026-04-09 | PXD075275 | Pride
Project description:Global proteomics dataset for K-GG ubiquitin profiling of DLD-1 and MDA-MB-231 cells treated with the selective USP9X inhibitor WEHI-092 at 10 µM for 30 min, 6 h, and 24 h (and DMSO-treated control). This dataset also includes DLD-1 cells treated with FT671 (USP7 inhibitor) at 10 µM for 30 min and 6 h. Sample IDs: #1-5 Control 30 min DLD-1 #6-10 FT671 30 min DLD-1 #11-15 WEHI-092 30 min DLD-1 #16-20 Control 360 min DLD-1 #21-25 FT671 360 min DLD-1 #26-30 WEHI-092 360min DLD-1 #31-35 Control 30 min MDA-MB-231 #36-40 WEHI-092 30 min MDA-MB-231 #41-45 Control 360 min MDA-MB-231 #46-50 WEHI-092 360 min MDA-MB-231 #51-55 Control 24 h MDA-MB-231 #56-60 WEHI-092 24 h MDA-MB-231
2026-04-09 | PXD074673 | Pride
Project description:1. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and MCF12A cells were treated with DMSO (vehicle control) or SU056 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates. 2. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the resulting soluble and insoluble fractions were determined.3. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 YBOX1 KD cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the soluble fractions were determined.
2024-04-04 | PXD042380 | Pride
Project description:1. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated for 6h with DMSO or SU212 and incubated at different temperatures and protein differences in the soluble fractions were determined. 2. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and BT549 cells were treated with DMSO (vehicle control) or SU212 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates.
2025-10-10 | PXD061466 | Pride
Project description:Expression data from MDA-MB-231 cells treated with dinaciclib
| PRJNA348737 | ENA
Project description:Expression data from parental MDA-MB-231 cells and MDA-MB-231(SA) variant
| PRJNA124283 | ENA
Project description:PAD4 is overexpressed in many cancer cells. We developed PAD inhibitors that efficiently inhibit the cancer cell growth. One inhibitor YW3-56 could efficently induce cell death of triple negative breast cancer MDA-MB-231 cells. We used microarray to detail the global gene expression of MDA-MB-231 before and after YW3-56 treatment and identify significant up-regulated or down-regulated genes by YW3-56
2015-05-21 | GSE46590 | GEO
Project description:Expression data from MDA-MB-231 cells treated with vehicle or YW3-56
2025-01-24 | E-GEOD-46590 | ExpressionAtlas